GEOVAX LABS, INC. (GOVX) Fair Value & Analysis
Healthcare · US · Market cap $3.7M
GEOVAX LABS, INC.
GOVX · US
Fair value as of: Aug 18, 2026
From 1 valuation models · updated today
Share price −32.8% over the past month.
A solid business, but screening 18% overvalued on our models.
What matters now
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($0.3500 to $0.6700) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.
How to read this chart
60‑month range $0.6550 – $2,284 · fair‑value band $0.3500 – $0.6700 · the $0.6550 price screens above the $0.5400 fair value. Dashed = 300-day average. As of Aug 18, 2026.
Analysis
GEOVAX LABS, INC. (GOVX) currently trades at $0.6550, while our model-based Fair Value estimate is $0.5400, implying the stock looks roughly 17.6% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $852K. The balance sheet holds a net cash position of $2.2M. Fundamentals as of Aug 18, 2026
Our scenario range runs from $0.3500 (bear case) to $0.6700 (bull case); at $0.6550, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -18%, GOVX screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when GOVX reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 0
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
Full company description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GEOVAX LABS, INC. reported revenue of $2.5M in FY2025 versus $385K in FY2021, a compound +59.5%/yr. Reported net income was −$21.5M in FY2025.
GOVX screens 18% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 599 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Regeneron Pharmaceuticals, Inc REGN | $797.99 | $594.40 | -26% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,037 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
Compare GEOVAX LABS, INC. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is GEOVAX LABS, INC. (GOVX) overvalued or undervalued?
What is the fair value of GOVX?
What is the quality score of GOVX?
What is the revenue of GEOVAX LABS, INC. (GOVX)?
What is the net profit margin of GOVX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track GEOVAX LABS, INC. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.